The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwAL 2025 | One big question with John DiPersio: what AML advance could transform frontline care in three years?
In this special ‘One Big Question’ segment, John DiPersio, MD, PhD, Washington University School of Medicine, St. Louis, MO, shares his perspectives on the most important trial or development poised to transform frontline treatment in acute myeloid leukemia (AML) over the next three years. He highlights the potential of reduced intensity induction regimens, which may lead to a paradigm shift in treatment outcomes. This interview took place at the 7th International Workshop on Acute Leukemias (iwAL 2025), held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
